A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
M V Lenti,D G Ribaldone,F Borrelli de Andreis,M Vernero,B Barberio,M De Ruvo,E V Savarino,T Kav,A Blesl,M Franzoi,H P Gröchenig,D Pugliese,G Ianiro,S Porcari,G Cammarota,A Gasbarrini,R Spagnuolo,P Ellul,K Foteinogiannopoulou,I Koutroubakis,K Argyriou,M Cappello,A Jauregui-Amezaga,M G Demarzo,N Silvestris,A Armuzzi,F Sottotetti,L Bertani,S Festa,P Eder,P Pedrazzoli,A Lasagna,A Vanoli,G Gambini,G Santacroce,C M Rossi,M Delliponti,C Klersy,G R Corazza,A Di Sabatino,European Consortium for the study of immune checkpoint inhibitor-induced colitis,C Mengoli,N Aronico,F Lepore,G Broglio,S Merli,G Natalello,E Alimenti,D Scalvini,S Muscarella,F Agustoni,A Pagani,S Chiellino,S Corallo,V Musella,R Cannizzaro,M Vecchi,F Caprioli,R Gabbiadini,A Dal Buono,A Premoli,L D Locati,A Buda,A Contaldo,A Schiepatti,F Biagi,D Morano,M Cucè,A Kotsakis,G De Lisi
DOI: https://doi.org/10.1016/j.esmoop.2024.103632
IF: 6.883
ESMO Open
Abstract:Background: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis. Materials and methods: This was a retrospective, European, multicentre study. Endoscopy/histology-proven ICI-induced colitis patients were enrolled. The 12-month clinical remission rate, defined as a Common Terminology Criteria for Adverse Events diarrhoea grade of 0-1, and the correlates of 12-month remission were assessed. Results: Ninety-six patients [male:female ratio 1.5:1; median age 65 years, interquartile range (IQR) 55.5-71.5 years] were included. Lung cancer (41, 42.7%) and melanoma (30, 31.2%) were the most common cancers. ICI-related gastrointestinal symptoms occurred at a median time of 4 months (IQR 2-7 months). An inflammatory bowel disease (IBD)-like pattern was present in 74 patients (77.1%) [35 (47.3%) ulcerative colitis (UC)-like, 11 (14.9%) Crohn's disease (CD)-like, 28 (37.8%) IBD-like unclassified], while microscopic colitis was present in 19 patients (19.8%). As a first line, systemic steroids were the most prescribed drugs (65, 67.7%). The 12-month clinical remission rate was 47.7 per 100 person-years [95% confidence interval (CI) 33.5-67.8). ICI was discontinued due to colitis in 66 patients (79.5%). A CD-like pattern was associated with remission failure (hazard ratio 3.84, 95% CI 1.16-12.69). Having histopathological signs of microscopic colitis (P = 0.049) and microscopic versus UC-/CD-like colitis (P = 0.014) were associated with a better outcome. Discontinuing the ICI was not related to the 12-month remission (P = 0.483). Four patients (3.1%) died from ICI-induced colitis. Conclusions: Patients with IBD-like colitis may need an early and more aggressive treatment. Future studies should focus on how to improve long-term clinical outcomes.